The assets acquired include products such as the DSB (Detachable Silicone Balloon) and the NDSB (Non-Detachable Silicone Balloon), also known as the Endeavor Balloon Catheter, both of which have been cleared for marketing by the FDA and through CE marking in Europe. The acquisition also included other neurovascular devices and Intellectual Property (IP) of StarFire. The remaining StarFire IP is focused on advanced intracranial aneurysm treatment devices that are in development.
Martin Dieck, president and CEO of Nfocus, said: “The combination of StarFire’s existing FDA-cleared devices and advanced aneurysm cover technology fits perfectly with the Nfocus product platform.”